Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 262-553-6 | CAS number: 60996-20-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Based on available information, it is concluded that potassium cryolite does not exhibit any potential for mutagenicity.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Description of key information
No in vivo data on potassium cryolite are available; however, two negative in vivo bone marrow chromosome aberrations assays are available on a structural analogue of potassium cryolite, sodium cryolite (trisodium hexafluoroaluminate). Taking into account the structural similarity of two substances and their comparable toxicological profiles, it is considered acceptable to derive information on in vivo genotoxicity of potassium cryolite by read-across from sodium cryolite. Consequently, it is concluded that potassium cryolite is not genotoxic in vivo.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
In vitro gene mutation study in bacteria
Potassium cryolite was examined for mutagenic activity in the Ames test (OECD guideline 471 and GLP compliant) using Salmonella typhimurium strains TA 1535, TA 1537, TA 98, TA 100 and the tryptophan-requiring Escherichia coli strain WP2 uvrA, in the absence and presence of metabolic activation (CiTox, 2017). The test item concentrations in the Initial Mutation Test and in the Confirmatory Mutation Test (5 strains) were 5000, 1581, 500, 158.1, 50, 15.81 and 5 (Confirmatory only) μg/plate. The mean values of revertant colonies of the solvent control plates were within the historical control range, the reference mutagens showed the expected increase in the number of revertant colonies, the viability of the bacterial cells was checked by a plating experiment in each test. At least five analyzable concentrations were presented in all strains of the main tests. The tests were considered to be valid. Potassium cryolite did not induce a dose-related increase in the number of revertant (His+) colonies in each of the four tester strains (TA 1535, TA1537, TA98 and TA100) and in the number of revertant (Trp+) colonies in tester strain WP2uvrA both in the absence and presence of S9-metabolic activation. Based on the results of this study it is concluded that Potassium cryolite is not mutagenic in the Salmonella typhimurium and in the Escherichia coli reverse mutation assay.
In vitro gene mutation study in mammalian cells
Since no in vitro gene mutation study in mammalian cells is available for potassum cryolite, the results from the structural analogue multiconstituent aluminium potassium fluoride are used instead (for details see Read-across justification as attached in section 13).
In a study according to OECD guideline 476 and in compliance with GLP, multiconstituent aluminium potassium fluoride was examined for its potential to induce gene mutations at the TK-locus of cultured mouse lymphoma L5178Y cells (TNO, 2010a). One assay was conducted in which 7 duplicate cultures were treated for 24 hours and 4 hours in the absence and presence of S9-mix, respectively. The test substance was suspended in dimethyl sulfoxide (DMSO) prior to testing. Treatment with the positive controls yielded the expected significant increases in mutant frequency compared to the negative control.
The highest concentration of aluminium potassium fluoride tested and evaluated for mutagenicity was 10 mmol/L in both the absence and presence of S9-mix. Aluminium potassium fluoride was cytotoxic in both the absence and presence of S9-mix. In the absence of S9-mix cytotoxicity resulted in a reduction in initial cell yield and suspension growth at and above 1.2 mmol/L. The relative total growth (RTG) value at the highest concentration tested and evaluated for mutagenicity (10 mmol/L) was 29% (mean of duplicate cultures). In the presence of S9-mix, cytotoxicity was observed at and above 2.5 mmol/L; the RTG at the highest concentration tested and evaluated for mutagenicity (10 mmol/L) was 61% (mean of duplicate cultures).In both the absence and presence of S9 -mix no increase in mutant frequency was observed at any test substance concentration evaluated.
In vitro and in vivo chromosome aberration test
For potassium cryolite, no information is available on the potential to induce chromosome aberrations (clastogenicity). Therefore the results from the structural analogues multiconstituent aluminiumpotassium fluoride (in vitro) and sodium cryolite (in vitro and in vivo) are used instead (for details see Read-across justification as attached in section 13).
In a chromosome aberration test with human lymophocytes according to OECD Guideline 487, multiconstituent aluminium potassium fluoride did not induce an increase in the number of micronuclei in human lymphocytes at dose levels up to 1500 µg/ml using pulse treatment with 4 hr exposure duration (with and without S9 mix). However, in a continuous treatment experiment using longer exposure duration times of 20 hr, aluminium potassium fluoride was found to induce a statistically significant increase in the number of micronuclei at concentrations 200 µg/ml and above. In vivo mutagenicity data on multiconstituent aluminium potassium fluoride are not available.
Sodium cryolite did not induce unscheduled DNA synthesis in rat hepatocytes at dose levels up to 50 µg/ml or increases in chromosome aberration frequencies in human lymphocytes up to 1000 µg/ml (with and without metabolic activation, exposure duration 3-4 hours).
Two in vivo cytogenicity tests are available for sodium cryolite. One bone marrow chromosome aberration test, in which male Crl:CD BR Sprague-Dawley rats were exposed by inhalation to 4.6 mg/m3 cryolite for 13 weeks, was run within the 13-week study on repeated dose toxicity (Bayer AG, 1997a). Increased inorganic fluoride concentrations in urine, bones, and teeth were evident, indicating that the test substance has reached the bone marrow. No effect on mitotic activity was observed. Furthermore, no evidence of clastogenicity was observed in the other in vivo bone marrow chromosomal aberration test, in which male and female Crl:CD BR Sprague-Dawley rats were exposed by snout-only inhalation to 2130 mg/m3 cryolite for 6 hours (Huntingdon Life Sciences Ltd., 1997 / Bayer AG, 1997b). Bone marrow cells were sampled after recovery periods of 16, 24 and 48 hours. No clinical signs or mortalities were induced. All experimental parts were run in compliance with GLP and according to OECD guideline 475. In summary, the available data provide conclusive evidence that sodium cryolite does not induce chromosome aberrations in vivo.
Justification for classification or non-classification
Based on the available data and in accordance with EU Classification, Labeling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008, classification is not necessary for mutagenicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.